Phase 1/2 Open Label, Dose-escalation Study of the Safety and OcUlar Tolerability of a Single Intravitreal Injection of RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration (SUSHI)
Phase of Trial: Phase I/II
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs RBM 007 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; First in man
- Acronyms SUSHI
- Sponsors Ribomic
- 02 Jul 2019 Status changed from recruiting to completed.
- 17 Jun 2019 According to a Ribomic media release, additional data analyses of this study are on-going and will be presented at future medical meetings.
- 17 Jun 2019 Results presented in a Ribomic Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History